Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Notch1 O-GlcNAcylation drives tumor stemness and mechanoadaptation to a stiff microenvironment and promotes chordoma recurrence
Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu
Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu
View: Text | PDF
Research Article Cell biology Oncology

Notch1 O-GlcNAcylation drives tumor stemness and mechanoadaptation to a stiff microenvironment and promotes chordoma recurrence

  • Text
  • PDF
Abstract

Chordomas are rare malignant osseous neoplasms with a striking rate of recurrence. Primary chordomas typically originate from embryonic notochord remnants, whereas recurrent chordomas usually stem from tumor cells infiltrating bone or cartilage after surgery. Clinically, the recurrent chordomas exhibit a stiffer extracellular microenvironment (ECM) than primary tumors. Intriguingly, this study identified cytoskeleton rearrangement, stress fiber reorganization, enhanced stemness, and Notch signaling activation in recurrent chordoma tissues or cell lines surviving stiff substrates, indicating the critical roles of mechanical remodeling and tumor stemness in stiffness resistance. We propose a potentially novel recurrence model where tumor cells experience mechanoadaptive organization, which enables them to resist stiff microenvironment-induced cell death. O-GlcNAcylation of Notch1 intracellular domain (NICD1) is central to this process. Mechanistically, the stiff ECM-driven ligand-independent phosphorylation of EPHA2 sequentially activated LYN kinase and subsequently triggered O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) activity by phosphorylating Y989 and Y418, critical residues for OGT glycosyltransferase activity; this induced NICD1 O-GlcNAcylation at T2063, T2090, and S2162, specifically promoting transcription of mechanical and stemness-related genes. MIR31 deletion upregulated LYN, enhancing stiffness perception and promoting O-GlcNAc addition to NICD1, finally resulting in mechanoadaptation- and tumor stemness–driven recurrence. Consequently, MIR31 deletion is a potential biomarker for recurrence and patient stratification in Notch- or OGT-targeted therapies.

Authors

Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu

×

Figure 4

O-GlcNAcylation of T2063, T2090, and S2162 enhances NICD1 stability and transactivation activity.

Options: View larger image (or click on image) Download as PowerPoint
O-GlcNAcylation of T2063, T2090, and S2162 enhances NICD1 stability and ...
(A) WB was used to detect the effect of pro–O-GlcNAc treatment on the half-lives of NICD1 in MUG-Chor1 cells and 293T cells treated with cycloheximide (CHX, 40 μM). (B) IP was used to assess the effects of pro–O-GlcNAc and OSMI-1 on the interaction between NUMB and NICD1 and K48-linked polyubiquitination of NICD1. (C) Chordoma cells expressing NUMB-Myc and NICD1-HA were treated with incrementally increased PUGNAC and GlcNAc, followed by IP assay to assess the interaction between NUMB and NICD1. (D) ChIP analysis was used to identify the enrichment of NICD1 on HES1 promoter in response to PUGNAC and GlcNAc. (E–H) ChIP-seq in MUG-Chor1 cells expressing NICD1-Flag with or without PUGNAC and GlcNAc treatment, cell extracts of which were pulled down by Flag. (E and F) Location and quantification of increased DNA pulled down by O-GlcNAcylated NICD1 compared with NICD1 was analyzed. Enrichment of upregulated genes is shown in G. (H) The peak on promoter regions of specific genes was shown using IGV. (I) IP and MS assay in MUG-Chor1 cells purified by anti-Flag affinity gel to determine the O-GlcNAcylation residues of NICD1. O-GlcNAc of WT and mutant NICD1 was determined. (J and K) IP and Duolink PLA to determine O-GlcNAcylation of WT and mutant NICD1 (carrying combined mutation of T2063A/T2090A/S2162A) in response to PUGNAC and GlcNAc in MUG-Chor1 cells. Scale bar: 50 μm. (L) IP was used to determine the effect of PUGNAC and GlcNAc on ubiquitination of WT and mutant NICD1 in MUG-Chor1 cells. (M) Dual luciferase reporter assay was used to detect Notch signaling activity in MUG-Chor1 cells with endogenous NICD1 knockout. (N) ChIP assay shows binding of WT and mutant NICD1 to the promoter region of HES1 in MUG-Chor1 cells. (O) Phalloidin staining and IF were used to analyze F-actin, VCL, and focal adhesions in MUG-Chor1 cells with endogenous NICD1 knockout. Scale bar: 10 μm. (P) TUNEL assay was used to assess the effect of OGT ectopic expression on WT and mutant NICD1 in chordoma cells with endogenous NICD1 knockout, which were cultured on substrates with different stiffnesses. WT, WT NICD1; MT, T2063A/T2090A/S2162A NICD1. Data in D, K, M, N, and P are presented as mean ± SD. Statistical analysis was performed using unpaired Student’s t test (D) and 1-way ANOVA (K, M, N, and P). *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts